The return on investment of up to $4,637 per vaccination course translates to billions of dollars in net monetary benefits to society, the authors say.
Data from 90 US hospitals show an overall 8.3% mortality rate for patients with invasive pneumococcal disease and non-invasive, all-cause pneumonia.
At 48 hospitals in Michigan, 1 in 8 adult patients treated for pneumonia had an improper diagnosis, and most of them received a full course of antibiotics.
Clinical trial and real-world data indicate the pneumococcal conjugate vaccine candidate V116 covers the serotypes responsible for most pneumococcal disease in older adults.
A literature review found pneumococcal conjugate vaccines were associated with some protection against flu and other viral respiratory tract infections.
The results of a randomized trial suggests rapid syndromic PCR tests could complement or replace culture-based diagnostic methods for pneumonia.
At least half of US adults hospitalized with uncomplicated community-acquired pneumonia in 2020 received 7 days or more of antibiotics.
Researchers say antibiotic trials in children diagnosed as having community-acquired pneumonia likely include many children without radiographic pneumonia.
Investigators say the strategy is readily applicable in low- and middle-income countries, where high rates of ventilator-associated pneumonia drive antibiotic use.
The goal of the intervention was to reduce diagnostic error for ventilator-associated pneumonia.
